Lentigen Corporation is a privately owned biotechnology company focused on the development of lentiviral vector technology for a wide range of therapeutic, vaccine, and research applications in biotechnology and medicine. Lentiviral vectors are widely recognized by the scientific community as the most efficient method for delivery of genetic sequence information into cells to reprogram their function. Lentigen is a highly collaborative company, co-developing Lentiviral vector-based products across a broad spectrum of bench to clinical applications.
